Search
aramchol
Indications:
- non-alcoholic fatty liver disease (NASH)
Mechanism of action:
- modulate stearoyl-CoA desaturase-1 (SCD1)
- reduces liver fat, improves liver histopathology
General
metabolic agent (metabolic modifier)
enzyme inhibitor
Database Correlations
PUBCHEM cid=18738120
References
- Walker M
Novel SCD1 Modulator Reduced Liver Fat in NASH Patients -
Dose-response pattern seen for aramchol in phase IIb ARREST trial.
MedPage Today. Nov 14, 2018
https://www.medpagetoday.com/meetingcoverage/aasld/76347